Portal de Periódicos da CAPES

Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure

2003; Elsevier BV; Volume: 92; Issue: 5 Linguagem: Inglês

10.1016/s0002-9149(03)00742-2

1879-1913

Gregory de Lissovoy, David M. Stier, Gabrielle Ciesla, Mark A. Munger, Andrew J. Burger,

Health Systems, Economic Evaluations, Quality of Life

Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.